Table 3. Exercise intervention significantly decreases fall rate in E4 carriers.
Fall rate per 1,000 participant-days1 | |||||||
---|---|---|---|---|---|---|---|
Genotype | Month | N | Mean fall rate | Genotype | Month | N | Mean fall rate |
E2− | B | 109 | 3.47 | E4− | B | 97 | 2.52 |
1 | 109 | 4.89 | 1 | 97 | 5.50 | ||
3 | 106 | 1.89 | 3 | 94 | 2.13 | ||
6 | 105 | 2.54 | 6 | 93 | 2.87 | ||
9 | 105 | 1.59 | 9 | 93 | 2.15 | ||
12 | 105 | 2.54 | 12 | 93 | 3.94 | ||
E2+ | B | 17 | 1.63 | E4+ | B | 29 | 5.56 |
1 | 17 | 7.84 | 1 | 29 | 4.60 | ||
3 | 16 | 4.17 | 3 | 28 | 2.38 | ||
6 | 16 | 6.25 | 6 | 28 | 3.57 | ||
9 | 16 | 2.08 | 9 | 28 | 0* | ||
12 | 16 | 6.25 | 12 | 28 | 0*** |
1Fall rate was calculated as (# participant-falls/# participant-days) × 1000. The fall rate of E4 carriers per 1000 participant-days decreased from 5.56 falls per 1000 participant days to 0 from baseline to month 12 (p = 0.043). There was a trend toward higher fall rate among E4 carriers versus E4 non-carriers at baseline (2.52 per 1000 participant-days versus 5.56, p = 0.059). However, after exercise intervention, E4 carriers demonstrated a significantly lower fall rate when compared with E4 non-carriers at both the 9 (2.15 versus 0, * p = 0.013) and 12 month (3.94 versus 0, *** p = 0.002) time periods. Abbreviation: B: baseline.